[Impact of COVID-19 pandemic on information management and adherence to replacement therapy with AAT of patients with alpha-1 antitrypsin deficiency (AATM)]. / Auswirkungen der COVID-19-Pandemie auf das Informationsmanagement und die Therapieadhärenz von substituierten Patienten mit Alpha-1-Antitrypsin-Mangel (AATM).
Pneumologie
; 76(7): 494-498, 2022 Jul.
Article
in German
| MEDLINE | ID: covidwho-1900704
ABSTRACT
METHODS:
In March 2021, a 19-item survey was sent to 420 patients with AATD who were being treated with AAT replacement therapy (prolastin) and who participated in the German AlphaCare patient program.RESULTS:
The majority of the respondents (55.9%; 138) had been diagnosed with AATD ≥10 years prior to the survey and most (93.5%; 231) felt adequately informed about their disease through their physician, AlphaCare and Alpha1 Deutschland. The majority of respondents were concerned/very concerned about acquiring COVID-19. Only 1.2% of the respondents reported having been infected with SARS-CoV-2, less than the infection rate in the general population at that time (3.4%). Almost all of the respondents fully agreed/agreed that they had restricted their social contacts due to the pandemic. A substantial percentage of the responding patients fully agreed/agreed that they were concerned about being infected with COVID-19 during a visit at their doctor's office or clinic. Regarding AAT augmentation therapy, only 18 respondents reported discontinuing therapy during the pandemic, but most of these discontinuations were short-term - one was permanent.CONCLUSIONS:
These survey results suggest that AATD patients are well-informed about the risks of COVID-19 with their condition and practised self-protection measures. This may have resulted in an COVID-19 infection rate lower than the general population. Although respondents were concerned about exposure to COVID-19 in their doctor's office or clinic, very few discontinued therapy even temporarily.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Alpha 1-Antitrypsin Deficiency
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
German
Journal:
Pneumologie
Year:
2022
Document Type:
Article
Affiliation country:
A-1845-0160
Similar
MEDLINE
...
LILACS
LIS